Work

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

Year: 2020

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.2265

Authors: P.A. Konstantinopoulos, A.A. Gockley, N. Xiong, N. Tayob, C.N. Krasner, M. Buss, S. Campos, S. Schumer, A.A. Wright, J.F. Liu, M. Shea, Y. Oladapo, C. Castro, M.M. Polak, C. Whalen, S. Bouberhan, S.A. Cannistra, R.T. Penson, G. Fleming, U.A. Matulonis

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, University of Chicago

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Yale University, Array BioPharma, Regeneron Pharmaceuticals, Merck KGaA, Novocure, Astex Pharmaceuticals, Myriad Genetics, Incyte, Syndax Pharmaceuticals, Eisai, PharmaMar, Genentech, EMD Serono

OpenAlex ID: W3088447833

Cites:

Cited by: 11

Related to: 10